Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY – Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $22.44 and last traded at $22.91, with a volume of 372139 shares trading hands. The stock had previously closed at $23.90.
Daiichi Sankyo Stock Down 4.1 %
The company’s 50 day moving average price is $24.44 and its two-hundred day moving average price is $28.32. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06. The stock has a market cap of $43.72 billion and a P/E ratio of 26.64.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $0.22 earnings per share for the quarter. Daiichi Sankyo had a net margin of 13.62% and a return on equity of 14.53%. Equities analysts forecast that Daiichi Sankyo Company, Limited will post 0.73 earnings per share for the current year.
Daiichi Sankyo Company Profile
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.
Featured Articles
- Five stocks we like better than Daiichi Sankyo
- What Are the FAANG Stocks and Are They Good Investments?
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- How to Evaluate a Stock Before Buying
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- Basic Materials Stocks Investing
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.